In the US, pharma research firm Decision Resources has announced plans to acquire the Life Sciences business of Wood Mackenzie, which comprises market research, data and analysis on the biopharmaceutical and animal health industries. Terms of the deal were not disclosed.
Global research reports and consultancy firm Wood Mackenzie has been providing analysis on the energy and life sciences markets for more than 30 years. It will retain its energy business, while its Life Sciences unit will be integrated into Decision Resources’s drug markets’ market research and advisory services business by the end of the year.
Earlier in the year, Decision Resources announced that Providence Equity Partners had acquired majority control in the company, and that it would use the cash to fund its growth (www.mrweb.com/drno/news6820.htm
). CEO Peter Hoenigsberg explains that this latest acquisition is part of the firm’s strategy to expand its services in the healthcare industry – he comments: ‘Wood Mackenzie's quality insights and research adds yet another layer of expertise to our growing healthcare analysis businesses’.
Sarah Fuller, who heads the unit, says Wood Mackenzie’s key product lines will help shape her firm’s analysis of the commercial side of the pharmaceutical industry.
Decision Resources has offices in Boston, Nashville, Toronto, Brussels, London and Tokyo and is on the web at www.decisionresources.com
, while Wood Mackenzie is online at www.woodmacresearch.com